Cancer Immunotherapy Trials Network (CITN)

The Mission of the CITN is to select, design and conduct early phase trials using agents with known and proven biologic function and to provide the high quality immunogenicity and biomarker data essential to inform subsequent development pathways leading to the broad availability of these agents for treating patients with cancer.

Funded by the National Cancer Institute and the Fred Hutchinson Cancer Research Center, the CITN employs the collective expertise of top academic immunologists to conduct multicenter research on immunotherapy agents capable of unleashing patient immunity to fight their cancer.

By collaborating with member institutions, industry sponsors, and philanthropic foundations, we aim to spearhead the design and conduct of trials leading to ultimate regulatory approval of promising agents and to advance the knowledge of antitumor immunity and its application in immunotherapy.